Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis

Abstract

The invention relates to pharmaceutical compositions for the treatment of multiple sclerosis which comprises a zinc-hyaluronan complex, preferably a zinc-hyaluronan complex with a molecular weight of 800-1200 kDa, as active ingredient and a pharmaceutically acceptable carrier and/or additive. The process for the preparation of said pharmaceutical compositions as well as the therapeutic use thereof for the treatment of multiple sclerosis are also within the scope of the invention.

1 . A pharmaceutical composition for the treatment of multiple sclerosis which comprises a zinc-hyaluronan complex alone or together with a pharmaceutical acceptable carrier and/or additive.  
   
   
       2 . A pharmaceutical composition according to  claim 1 , wherein the zinc-hyaluronan complex has a molecular weight of 800-1200 kDa.  
   
   
       3 . A pharmaceutical composition according to  claim 1  to  2 , wherein the composition is in the form of solution.  
   
   
       4 . A pharmaceutical composition according to any of  claims 1  to  3 , wherein the composition is in the form of injection for subcutaneous, intramuscular or intravenous administration.  
   
   
       5 . A pharmaceutical composition according to any of  claims 1  to  3 , wherein the composition is in the form of infusion.  
   
   
       6 . Use of zinc-hyaluronan complex for the manufacture of a medicament for the treatment of multiple sclerosis.  
   
   
       7 . Use of zinc-hyaluronan complex according to  claim 6 , wherein the zinc-hyaluronan complex has a molecular weight of 800-1200 kDa.  
   
   
       8 . Use of zinc-hyaluronan complex according to  claim 6  to  7 , wherein the medicament manufactured is in the form of solution.  
   
   
       9 . Use of zinc-hyaluronan complex according to any of  claims 6  to  8 , wherein the medicament manufactured is in the form of injection, for subcutaneous, intramuscular or intravenous administration.  
   
   
       10 . Use of zinc-hyaluronan complex according to any of  claims 6  to  8 , wherein the medicament manufactured is in the form of infusion.  
   
   
       11 . A process for the preparation of a pharmaceutical composition for the treatment of multiple sclerosis, which comprises forming a mixture containing a zinc-hyaluronan complex active agent in admixture with a carrier and/or additive conveniently used in medicine to obtain the composition.  
   
   
       12 . A process according to  claim 11 , wherein the zinc-hyaluronan complex has a molecular weight of 800-1200 kDa.  
   
   
       13 . A process according to  claim 11  or  12 , wherein the pharmaceutical composition prepared is a solution.  
   
   
       14 . A process according to any of  claims 11  to  13 , wherein the pharmaceutical composition prepared is an injection for subcutaneous, intramuscular or intravenous administration.  
   
   
       15 . A process according to any of  claims 11  to  13 , wherein the pharmaceutical composition prepared is an infusion.  
   
   
       16 . A method of treating multiple sclerosis, which comprises administering to a person to be treated a therapeutically effective amount of zinc-hyaluronan complex alone or in the form of a pharmaceutical composition.  
   
   
       17 . The method according to  claim 16  wherein the zinc-hyaluronan complex has a molecular weight of 800-1200 kDa.  
   
   
       18 . The method according to  claim 16  or  17 , wherein the pharmaceutical composition is a solution.  
   
   
       19 . The method according to any of  claims 16  to  18 , wherein the pharmaceutical composition is an injection for subcutaneous, intramuscular or intravenous administration.  
   
   
       20 . The method according to any of  claims 16  to  18 , wherein the pharmaceutical composition is an infusion.